Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515297 | 0.93 | PIM3 (0.54) | TMEM97SIGMAR1BRAFPIM3RAF1 | |
| SCHEMBL2935119 | 0.91 | FYN (0.51) | BRAFPIM3RAF1FYNKDR | |
| Trifluoroacetic Acid SCHEMBL2927171 | 0.88 | PIM3 (0.51) | TMEM97SIGMAR1BRAFPIM3RAF1 | |
| SCHEMBL2933545 | 0.88 | FYN (0.59) | BRAFPIM3RAF1FYNMAPT | |
| SCHEMBL13515294 | 0.86 | KDR (0.47) | TMEM97SIGMAR1PIM3CYP3A4CYP2C9 | |
| SCHEMBL14269639 | 0.84 | PIM3 (0.55) | BRAFPIM3RAF1FYNKDR | |
| SCHEMBL2933495 | 0.84 | ADRA2A (0.52) | BRAFPIM3CYP2C9MCHR1 | |
| SCHEMBL2928960 | 0.84 | ALDH1A1 (0.50) | BRAFFYNCYP3A4MCHR1KDR | |
| SCHEMBL2926093 | 0.83 | IGF1R (0.50) | BRAFPIM3RAF1 | |
| SCHEMBL2932519 | 0.83 | BRAF (0.56) | BRAFMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | TMEM97 2346/4885SIGMAR1 1647/4885BRAF 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.